Chimerix shares surged more than 12 percent on Monday after reports surfaced that the Dallas, Texas patient diagnosed with Ebola last week would be treated with the company's experimental brincidofovir drug.
The drug received Emergency Investigational New Drug Applications (EINDA) from the U.S. Food and Drug Administration, the company said earlier.
Chimerix is working closely with the FDA to finalize future trials to assess the safety and effectiveness of the drug in patients.
An EINDA allows the FDA to authorize use of an experimental drug in an emergency situation that does not allow time for submission of a regular new drug application.
The World Health Organization on Friday updated its death toll from Ebola to at least 3,439 out of 7,492 suspected, probable or confirmed cases.